Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Akili Inc
Healthcare
P/NCAV
0.33x
Ticker
AKLI
Exchange
NASDAQ
Country
United States
Close
0.24 $
Mkt Cap
18.7M $
EV
-43.5M $
NCAV Burn Rate
47.6%
Current Ratio
6.02
Debt/Equity
0.22
EV/REV
-25.9x
EV/EBIT
0.7x
EV/FCF
0.8x
Dilution
0.1% p.A
Total Net Income
-154.5M $
Cheapness
100.0%
Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company’s approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average